Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine

V. R. Sheidler, David S Ettinger, R. B. Diasio, J. P. Enterline, M. D. Brown

Research output: Contribution to journalArticle

Abstract

Twenty cancer patients who received chemotherapy were entered into a double-blind crossover design antiemetic study comparing 1 mg levonantradol, and investigational synthetic cannabinoid, to 10 mg prochlorperazine. Sixteen patients completed the crossover. For each antiemetic course, four doses of each study medication were given intramuscularly 2 hours before chemotherapy and then 2, 6, and 10 hours after chemotherapy administration. There were no statistical differences in patients' responses to levonantradol and prochlorperazine. The frequency of side effects was greater with levonantradol than with prochlorperazine. The most common side effect of levonantradol were somnolence, dry mouth, dizziness, tachycardia, postural hypotension, and blurred vision, while those for prochlorperazine were somnolence, dry mouth, and tachycardia.

Original languageEnglish (US)
Pages (from-to)155-159
Number of pages5
JournalJournal of Clinical Pharmacology
Volume24
Issue number4
StatePublished - 1984

Fingerprint

Prochlorperazine
Antiemetics
Cross-Over Studies
Tachycardia
Drug Therapy
Mouth
Orthostatic Hypotension
Cannabinoids
Dizziness
nantradol
Neoplasms

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. / Sheidler, V. R.; Ettinger, David S; Diasio, R. B.; Enterline, J. P.; Brown, M. D.

In: Journal of Clinical Pharmacology, Vol. 24, No. 4, 1984, p. 155-159.

Research output: Contribution to journalArticle

@article{088967b1f0cb49dfb82fb5d9faed8263,
title = "Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine",
abstract = "Twenty cancer patients who received chemotherapy were entered into a double-blind crossover design antiemetic study comparing 1 mg levonantradol, and investigational synthetic cannabinoid, to 10 mg prochlorperazine. Sixteen patients completed the crossover. For each antiemetic course, four doses of each study medication were given intramuscularly 2 hours before chemotherapy and then 2, 6, and 10 hours after chemotherapy administration. There were no statistical differences in patients' responses to levonantradol and prochlorperazine. The frequency of side effects was greater with levonantradol than with prochlorperazine. The most common side effect of levonantradol were somnolence, dry mouth, dizziness, tachycardia, postural hypotension, and blurred vision, while those for prochlorperazine were somnolence, dry mouth, and tachycardia.",
author = "Sheidler, {V. R.} and Ettinger, {David S} and Diasio, {R. B.} and Enterline, {J. P.} and Brown, {M. D.}",
year = "1984",
language = "English (US)",
volume = "24",
pages = "155--159",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine

AU - Sheidler, V. R.

AU - Ettinger, David S

AU - Diasio, R. B.

AU - Enterline, J. P.

AU - Brown, M. D.

PY - 1984

Y1 - 1984

N2 - Twenty cancer patients who received chemotherapy were entered into a double-blind crossover design antiemetic study comparing 1 mg levonantradol, and investigational synthetic cannabinoid, to 10 mg prochlorperazine. Sixteen patients completed the crossover. For each antiemetic course, four doses of each study medication were given intramuscularly 2 hours before chemotherapy and then 2, 6, and 10 hours after chemotherapy administration. There were no statistical differences in patients' responses to levonantradol and prochlorperazine. The frequency of side effects was greater with levonantradol than with prochlorperazine. The most common side effect of levonantradol were somnolence, dry mouth, dizziness, tachycardia, postural hypotension, and blurred vision, while those for prochlorperazine were somnolence, dry mouth, and tachycardia.

AB - Twenty cancer patients who received chemotherapy were entered into a double-blind crossover design antiemetic study comparing 1 mg levonantradol, and investigational synthetic cannabinoid, to 10 mg prochlorperazine. Sixteen patients completed the crossover. For each antiemetic course, four doses of each study medication were given intramuscularly 2 hours before chemotherapy and then 2, 6, and 10 hours after chemotherapy administration. There were no statistical differences in patients' responses to levonantradol and prochlorperazine. The frequency of side effects was greater with levonantradol than with prochlorperazine. The most common side effect of levonantradol were somnolence, dry mouth, dizziness, tachycardia, postural hypotension, and blurred vision, while those for prochlorperazine were somnolence, dry mouth, and tachycardia.

UR - http://www.scopus.com/inward/record.url?scp=0021142573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021142573&partnerID=8YFLogxK

M3 - Article

C2 - 6373843

AN - SCOPUS:0021142573

VL - 24

SP - 155

EP - 159

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 4

ER -